Table 4.
Distribution of AT Outcomes by ART Regimen at Week 96
| NNRTI or PIa | NRTIa | ||||
|---|---|---|---|---|---|
| Week 96 | Overall (n = 30) | EFV (n = 13) | RTV/ATV (n = 17) | ABC/3TC (n = 11) | TDF/FTC (n = 19) |
| SAT density, HU | −104 (−107, −100) | −102 (108, −99) | −105 (−107, −102) | −99 (−104, −95) | −105 (−108, −103) |
| VAT density, HU | −90 (−94, −84) | −91 (−96, −86) | −88 (−93, −82) | −84 (−87, −81) | −91 (−94, −86) |
| Adipocyte area, μm2 | 2759 (2304, 3029) | 2455 (2158, 3007) | 2761 (2444, 3148) | 2488 (2072, 3029) | 2827 (2427, 3057) |
| SAT area-adipocyte size correlationb | −0.57 (0.003) | −0.60 (0.09) | −0.67 (0.005) | −0.73 (0.02) | −0.37 (0.18) |
| NNRTI or PIa | NRTIa | ||||
|---|---|---|---|---|---|
| 96-Week Change (%, P) | Overall (n = 30) | EFV (n = 13) | RTV/ATV (n = 17) | ABC/3TC (n = 11) | TDF/FTC (n = 19) |
| SAT density, HU | −3%, P = 0.01 | −1%, P = 0.70 | −3%, P = 0.003 | −1%, P = 0.50 | −3%, P = 0.02 |
| VAT density, HU | −6%, P < 0.001 | −4%, P = 0.08 | −8%, P = 0.004 | −5%, P = 0.25 | −7%, P = 0.002 |
| Adipocyte area, μm2 | 22%, P < 0.001 | 18%, P = 0.07 | 26%, P < 0.001 | 22%, P = 0.04 | 23%, P = 0.001 |
| 96-Week Change (%, P) | Overall (n = 30) | EFV + TDF/FTC (n = 8) | EFV + ABC/3TC (n = 5) | RTV/ATV + TDF/FTC (n = 11) | RTV/ATV + ABC/3TC (n = 6) |
|---|---|---|---|---|---|
| SAT density, HU | −3%, P = 0.01 | 1%, P = 1.00 | −2%, P = 0.63 | −3%, P = 0.004 | 1%, P = 0.81 |
| VAT density, HU | −6%, P < 0.001 | −4%, P = 0.30 | −6%, P = 0.25 | −8%, P = 0.004 | 2%, P = 0.81 |
| Adipocyte area, μm2 | 22%, P < 0.001 | 20%, P = 0.22 | 8%, P = 0.19 | 25%, P = 0.002 | 36%, P = 0.16 |
Median (IQR) reported. P values for percentage change overall or within treatment arms based on Wilcoxon signed-rank test.
Abbreviations: NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor.
a
Participants are in the EFV or RTV/ATV group and in the ABC/3TC or TDF/FTC arms.
b
Spearman ρ (P value).